Cipla gets USFDA approval for its generic acromegaly drug

23 May 2024 , 12:27 PM

Cipla announced on Wednesday that it has received approval from the US Food and Drug Administration (USFDA) to market a generic medication used to treat acromegaly and other related conditions. The approval includes multiple strengths of Lanreotide injection, a therapeutic equivalent generic version of Somatuline Depot Injection.

At the time of writing, the shares of Cipla were trading at ₹1500.15 which is a 1.20% gain than the previous close. The stock has gained over 61.24% in the last one year, and 19.90% since the beginning of the year. 

Lanreotide Injection is indicated for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumors. Somatuline Depot, the branded version, had sales of approximately USD 898 million in the US for the 12-month period ending March 2024, according to IQVIA (IMS Health).

For feedback and suggestions, write to us at [e-mail] 

For opening a demat account click on: https://www.indiainfoline.com/

For doing stock trading & investments, go to: https://ttweb.indiainfoline.com/trade/Login.aspx

For loans, go to: https://www.iifl.com/